Yazar "Kantar, Mehmet" seçeneğine göre listele
Listeleniyor 1 - 20 / 60
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Akut lösemili ve non-Hodgkin lenfomalı çocuklarda tiopürin S-metiltransferazın 8 gen polimorfizminin araştırılması(Ege Üniversitesi, 2009) Kantar, Mehmet; Kantar, MehmetAkut lenfoblastik lösemi ( ALL), akut myeloid lösemi (AML) ve non-Hodgkin lenfomalı (NHL) çocukların tedavisinde kullanılan 6 - merkaptopürin ve 6-tioguanin adlı ilaçlara bağlı sık hematoloji ve hepatik toksisite gelişmektedir. Bu ilaçları metabolize eden tiopirin-S-metil transferaz (TPMT) enziminin her toplumda değişik varyasyonları görülmektedir. TPMT 'nin bilinen mutant alleli enzim aktivitesini değiştirmektedir. Bu çalışmada TPMT geninin 8 mutant alleline bakılmıştır. Çalışmada 49 akut lösemi veya lenfoblastik lenfomalı çocukta yabanıl tip TPMT (*1) (%87.3) oranında bulunmuştur. TPMT*2(G238C) polimorfizmi 1 hastada (%2), TPMT*3B polimorfizmi (G460A) 10 hastada (%20.4) saptanmıştır. Bunun dışında bakılan TPMT* 3A, TPMT* 3C (A719G), TPMT* 3D, TPMT*4 (G--A), TPMT *5 (T146C), TPMT*6 (A539T), TPMT*7 (T681G) polimorfizmleri hiçbir hastada saptanamamıştır. Kontrol grubuna alınan 84 sağlıklı çocuğun %98.8 oranında yabanıl tip TPMT (*1) taşıdığı, 1 çocuğun (%1.2) TPMT* 3B polimorfizmi olduğu görülmüştür. Diğer polimorfizmler ise saptanamamıştır. Hasta ve kontrol grupları karşılaştırıldığında,kontrol grubundaki çocukların daha fazla yabanıl tip (wild)TPMT taşıdıkları görülmüştür (p=0.0001). Öte yandan TPMT*3B polimorfizminin hasta çocuklarda kontrol grubuna göre daha fazla olduğu saptanmıştır(p=0.0001).Hastalarda saptanan derece III/ IV hematoloji ve hepaik toksisite ile TPMT polimorfizmleri arasında ilişki bulunamamıştır. Bu nedenle idame tedavisi altında rutin TPMT bakılmasını önermiyoruz.;Tiopürin-S-Metil Transferaz, Lösemi, Lenfoma, PolimorfizmÖğe ASSESSMENT OF SCHOOL-RELATED PROBLEMS OF CHILDHOOD CANCER PATIENTS: A STUDY FROM WEST OF TURKEY(Wiley Periodicals, Inc, 2012) Yilmaz, Medine; Sari, Hatice Yildirim; Kantar, Mehmet; Aksoylar, Serap; Cetingul, Nazan; Erermis, SerpilÖğe Atypical teratoid/rhabdoid tumor of the central nervous system: clinicopathologic and immunohistochemical features of four cases(Springer, 2009) Ertan, Yesim; Sezak, Murat; Turhan, Tuncer; Kantar, Mehmet; Ersahin, Yusuf; Mutluer, Saffet; Vergin, Canan; Oniz, Haldun; Akalin, TanerAtypical teratoid/rhabdoid tumor (AT/RT) is a rare aggressive infantile neoplasm of uncertain origin. This study was performed to assess the clinicopathologic and immunohistochemical features of four AT/RT cases. Two cases were male and two were female, and their ages ranged from 8 to 103 months. Tumors were located in the cerebellum (two cases), frontoparietal lobe (one case), and third ventricle (one case). Histopathologically, the tumors were composed of rhabdoid cells and undifferentiated small cells mixed with epithelial or mesenchymal components. However, one of the tumors was composed predominantly of a mesenchymal component mimicking a sarcoma. Immunohistochemically, vimentin (4/4), epithelial membrane antigen (4/4), cytokeratin (3/4), smooth muscle actin (4/4), glial fibrillary acidic protein (4/4), S-100 (4/4), and synaptophysin (1/4) were positive in varying proportions, while desmin and INI-1 were negative in all the cases. All of the patients died within a mean of 14 months due to tumor progression despite the chemotherapy. Only one of our patients lived for 40 months after the diagnosis. In conclusion, AT/RTs are aggressive tumors. They can occur in a variety of locations, such as the third ventricle. Morphologically, a large spectrum can be seen, like predominantly sarcoma in appearance, but immunohistochemistry is helpful in the correct diagnosis.Öğe Biomarkers in pediatric tumors(Pergamon-Elsevier Science Ltd, 2014) Kantar, MehmetÖğe A BRIEF OVERVIEW TO PEDIATRIC GRAY ZONE LYMPHOMAS(Wiley, 2022) Ataseven, Eda; Ozek, Gulcihan; Ozsan, Nazan; Kamer, Serra; Anacak, Yavuz; Aksoylar, Serap; Kantar, Mehmet[No Abstract Available]Öğe Changes in the Prevalence of Coccidian Protozoa in Immunocompromised Patients Over the Last Decade(Galenos Yayincilik, 2021) Bagci, Ozlem Ulusan; Zorbozan, Orcun; Yetismis, Kardelen; Aydogdu, Sema; Ardeniz, Fatma Omur; Gokengin, Ayse Deniz; Kantar, MehmetIntroduction: Coccidian protozoal infection is one of the most important causes of diarrhea, which could prove to be fatal in immunosuppressed patients. The present study aimed to determine changes in the incidences and prevalence of coccidian protozoa in immunocompromised patients in two different time frames, and thus draw attention toward these neglected microorganisms. Materials and Methods: The present study involved retrospective analysis of 311 stool samples obtained from 311 immunocompromised patients, collected over two time frames (2009 and 2016-2019). Results: The study included 40.5% female and 37.6% pediatric immunocompromised patients (aged 0-18 years). In 2009, the incidences of Cryptosporidium spp. were 51.4% and this decreased to 41.6% in 2016-2019. Cyclospora spp. incidences decreased from 24.6% in 2009 to 9.8% in 2016-2019. Coccidian infection in pediatric patients was found to decrease over the stipulated time, where Cryptosporidium spp. incidences decreased from 63.9% to 34.6% and Cyclospora spp. detection rate decreased from 30.6% to 4.9%. In adults, detection rate for Cryptosporidium spp. changed from 47% to 47.8%, while Cyclospora spp. incidences changed from 22.5% to 14.1%, over the period of 10 years. Conclusion: The study demonstrated no significant changes in coccidian parasitic detection rates in immunocompromised adults over the period of 10 years, which remained high. However, a significant decrease in the detection rates of both Cryptosporidium and Cyclospora spp. was reported in pediatric patients over the years. A comparison with previously reported data revealed higher detection rates of coccidian parasite in immunocompromised patients as compared to the general patient population. These results also highlighted the importance of detailed patient information, especially clinical diagnosis and drug usage, to ensure application of appropriate diagnostic methods for laboratory evaluation of the stool samples obtained from immunocompromised patients. This will further aid in early diagnosis and management of such infections.Öğe Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1(Springer, 2019) Turan, Caner; Kantar, Mehmet; Aktan, Cagdas; Kosova, Buket; Orman, Mehmet; Bilgen, Cem; Kirazli, TayfunPurpose We aimed to investigate the cisplatin-related hearing toxicity and its possible relationship with polymorphic variants in DNA repair genes, ERCC1, ERCC2, and XRCC1. Methods Fifty patients treated with cisplatin in the past were included in the study. There were 29 females and 21 males; mean age 13.4 +/- 6.0 years). the polymorphism in DNA repair genes was studied using primer and probes in Light Cycler device after DNA isolation was carried out with PCR technique. the polymorphisms and clinical risk factors were evaluated using Chi square test and logistic regression modelling. Results the patients had hearing loss in 44%. For ERCC1 gene, the patients with hearing loss had 50% of GG (wild type), 40.9% of AG and 9.1% of AA genotypes, while the patients without hearing loss had 28.6% of GG, 53.5% of AG, and 17.9% of AA genotypes. For ERCC2 gene, the patients with hearing loss had 18.2% of GG (wild type), 40.9% of TG, and 40.9% of TT genotypes, while the patients without hearing loss had 10.7% of GG 39.3% of TG, and 50% of TT genotypes. For XRCC1 gene, the patients with hearing loss had 18.2% of CC (wild type), 59.1% of CT, and 22.7% of TT genotypes, while the patients without hearing loss had 35.7% of CC, 50% of CT, and 14.3% of TT genotypes. There was no statistically significant association among the groups (p = 0.24). Conclusion We did not find a relationship between DNA repair gene polymorphisms and hearing toxicity of cisplatin.Öğe Clinical and Molecular Spectrum of TuberousSclerosis Complex Patients: Identification of ThreeNovel Mutations(2021) Işık, Esra; Tekgül, Hasan; Kantar, Mehmet; Çoğullu, Özgür; Atik, Tahir; Solmaz, Aslı Ece; Terek, DemetObjective: Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome. TSC arises from mu tations in either TSC1, at 9q34, or TSC2, at 16p13.3. Skin lesions, such as hypomelanotic macules, facial angiofibromas,shagreen patches, and ungual fibromas, are frequently seen in these patients. The present study aims to investigate clinicalmanifestations, molecular findings and phenotype-genotype correlations in 17 patients with TSC. Materials and Methods: TSC1 and TSC2 molecular analyses were performed on a next-generation sequencing platform(Illumina MiSeq). Variant interpretation was made in accordance with the American College of Medical Genetics 2015 rec ommendations. Results: Four patients carried a heterozygous mutation in TSC1, while the remaining seven carried mutations in TSC2.Three novel variants in TSC2 were defined. Sequencing failed to detect a mutation in six patients. In only one of these pa tients, multiplex ligation-dependent probe amplification (MLPA®) could be performed, and a large deletion in the TSC1 genewas detected. A wide spectrum of phenotypic features was noted throughout the study group. Dermatological findings wereobserved in almost all patients. Conclusion: In this study, in addition to the three novel mutations reported herein, the spectrum of TSC1 and TSC2 genemutations and their phenotypes were reported.Öğe Çocukluk çağı hastalıklarında kemik iliği ve kök hücre nakli sonuçları(2001) Kansoy, Savaş; Aksoylar, Serap; Kantar, MehmetKemik iliği Transplantasyonu (KİT), kemoterapötik ajanları çok yüksek dozlarda, çoğu zaman radyoterapi ile birlikte, nonhematolojik toksisiteler sınırında hastaya vermek ve böylece maksimal antitümör etki veya eradikasyonu sağlayıp, oluşan kemik iliği supresyonunu da allojenik, sinjeneik veya otolog koşullarda, transplantasyonla desteklemek esasına dayanan bir uygulamadır. Başlangıçta maliyn hastalıklarda uygulanan KİT'nun bir başka uygulama alanı ise bazı doğmalık hastalıklarda, Kİ hücrelerinin sağlıklı olanlarla değiştirilmesi olmaktadır. Bu çalışmada, pediatrik yaş grubundaki maliyn ve maliyn olmayan hastalıklara sahip çocuklarda, kemik iliği ve periferik kan kök hücre naklinden oluşan "Kök Hücre Nakli" uygulandı. Çalışma, Sosyal Sigortalar Kurumu (SSK) Tepecik Eğitim Hastanesi ve Ege Üniversitesi Çocuk Sağlığı ve Hastalıkları Anabilim Dalı Çocuk Onkoloji ve Kemik iliği Transplantasyonu Merkezleri'nde yapıldı. Kasım 1994 - Haziran 2000 yılları arasında toplam 38 olguya otolog veya allojenik transplantasyon uygulandı. Transplantasyon işlemi için maliyn hastalık gurubunda 9 Akut Myeloblastik Lösemi (AML), 5 Akut Lenfoblastik Lösemi (ALL), 3 Kronik Myelositer Lösemi, 3 Hodgkin Hastalığı (HD) ve 5 Solid Tümör olgusu, maliyn olmayan grupta ise 10 Talasemi Majör (TM), bir Aplastik Anemi (AA)'Iİ ve 2 ağır kombine yetmezliği (SCID) olan hastalar seçildi. Üç TM'lu ve bir HD'lı olguya iki kez allojenik veya otolog TX (ikincil Transplantasyon / Second TX) uygulandı. Olguların 20'sı (%52.6) kız, 18'i (%47.4) erkek, ilk tanı anında yaş ortalaması 94.1±67.3 ay (3 - 200), ortanca değer 113.5 ay idi. Transplant zamanındaki yaş ortalaması 119.2 ± 55.7 (8 - 207), ortanca değer 125.0 ay idi. Otolog transplantasyon grubunda 16 olguya periferik kök hücre (OPKH) uygulandı. Allojenik transplantasyon gurubunda toplam 22 olgunun 16'sına kemik iliği transplantasyonu (AKİT), 6 hastaya ise periferik kök hücre nakli (APKH) yapıldı. Allojenik transplantasyonların biri hariç tümünde HLA doku gurupları tam uygun olan kardeş donörler seçildi. Tüm olgular birlikte değerlendirildiğinde; TX yaşı 119.3 ± 55.7 ay (8 ay - 17 yaş), Kök hücre miktarı ortanca 4.46 x 108 (1.50 - 13.2), engraftment günü ortalama 16.4 ± 5.3 gün (7 - 28 gün), lökosit düzelmesi 22.3 ± 17.9 gün (12 - 66 gün), platelet düzelmesi ortalama 26.9 ± 27.3 gün (13 - 67 gün), Post TX DFS 30.7±18.1 ay (5 - 66 ay), Post TX OS ortalama 60.5 ± 52.2 ay (4.5 - 238 ay) bulundu. Sonuç olarak, maliyn ve bazı maliyn olmayan hastalıklarda "Kemik iliği" ve "Kan Kök Hücre" nakilleri ile kür şansı elde edilebilmektedir. Maliyn hastalığı olanlar primer hastalık ile beraber kemoterapi ve radyoterapinin erken ve geç etkilerinden uzaklaşmaktadır. Bazı doğmalık kan hastalıklarında, hasta transfüzyon ihtiyacından kurtulmakta ve geç endokrin etkilere maruz kalmamakta, normal bir yaşam süresine kavuşabilmektedir.Öğe Çocukluk çağı maliynitelerinde Epstein-Barr virüs seropozitifliği(2001) Ülger, Zülal; Büyükavcı, Mustafa; Çetingül, Nazan; Kantar, Mehmet; Aydemir, Şöhret; Kansoy, Savaş; Kavaklı, KaanEpstein Barr virüsün (EBV) maliynite etyolojisindeki rolüyle ilgili birçok çalışma yapılmıştır. Bu çalışmaların sonuçları yapıldıkları bölgelere göre farklı sonuçlar içermektedir. Bizim çalışmamızda izlediğimiz 45 maliyniteli olgunun EBV seropozitifliği normal populasyonla karşılaştırıldı. Maliyniteli olgularda EBV IgG pozitifliği oranı % 93 iken, kontrol grubunda % 79 idi ve aradaki fark istatistiksel olarak anlamlıydı (p<0.05). Özellikle lenfomalı olgularda seropozitiflik % 100'e ulaşmaktaydı. Bu sonuçlar, maliyniteli olgularda EBV seropozitifliğinin yüksek olduğunu gösterdi. Daha geniş olgu grubunda ve doku örneklerinde EBV antikorlarının gösterilmesinin maliynite etiyopatogenezindeki rolünü açıklamada anlamlı olabileceğini düşündürdü.Öğe Comparison of malnutrition and malnutrition screening tools in pediatric oncology patients: A cross-sectional study(Elsevier Science Inc, 2021) Bicakli, Derya Hopanci; Kantar, MehmetObjectives: The aim of this study was to determine the prevalence of malnutrition, to compare nutritional evaluation tools, and to highlight the importance of nutritional status in pediatric oncology patients.& nbsp; Methods: This study evaluated the nutritional status, based on height, weight, and midupper arm circumfer-ence, of 170 patients ages 5 months to 18 years who were hospitalized at the Ege University Hospital Pediat-ric Oncology Clinic. The prevalence of malnutrition was determined using the malnutrition screening tools, STRONGkids (SK) and Pediatric Yorkhill Malnutrition Score (PYMS). Correlations, sensitivity, specificity, and the positive and negative predictive values between the screening tools were calculated.& nbsp; Results: In all, 68.2% of the patients were diagnosed with a solid tumor. According to SK, 59.4% had a moder-ate risk of malnutrition, and 40.6% had a high risk. According to PYMS, 30.6% of patients had a low to moder-ate risk of malnutrition, and 69.4% had a high risk of malnutrition. Minimal agreement was noted between SK and PYMS (Kappa value: 0.40 and 0.18, respectively). The sensitivity of PYMS was higher than that of SK (92.68 and 78.05, respectively). In total, 22.9% of the patients had a body mass index of <5%, and 21.2% had a midupper arm circumference of <5.& nbsp; Conclusions: The present findings show that, in general, pediatric oncology patients have a high risk of mal-nutrition. Although SK and PYMS do not differ significantly, PYMS has higher sensitivity for detecting malnu-trition. The nutritional status of pediatric oncology patients should be monitored using appropriate screening techniques throughout their treatment.& nbsp; (c) 2021 Elsevier Inc. All rights reserved.Öğe Cutaneous Side Effects of Chemotherapy in Pediatric Oncology Patients(Quadrant Healthcom Inc, 2015) Ceylan, Can; Kantar, Mehmet; Tuna, Arzu; Ertam, Ilgen; Aksoylar, Serap; Gunaydin, Asli; Cetingul, NazanÖğe Cytoprotective effect of amifostine in the treatment of childhood malignancies(Wiley-Liss, 2007) Midvat, Levent; Cetingul, Nazan; Kantar, Mehmet; Demirao, Bengu; Aksoylar, Serap; Kansoy, SavapÖğe Cytoprotective Effects of Amifostine in the Treatment of Childhood Malignancies(Wiley, 2009) Cetinguel, Nazan; Midyat, Levent; Kantar, Mehmet; Demirag, Bengue; Aksoylar, Serap; Kansoy, SavasBackground. Multi-systemic acute side effects occur, in response to intensive therapies that have been applied in childhood malignancies in recent years. Amifostine has rarely been used in the childhood cancers as a multisystemic protective agent for minimizing these side effects. Procedure. In this Study, the effectiveness of amifostine in combination with chemotherapy for childhood cancer treatment has been researched. Of 11 Subjects (2.5 months-17 years) 4 Subjects had leukemia, 4 had solid tumor, and 3 1 ad lymphoma. For these 11 subjects, 29 chemotherapy Courses were given in combination with amifostine, and 20 without amifostine. Their hematological, gastrointestinal and hepatic toxicity were evaluated according to the WHO toxicity criteria. Amifostine was given intravenously in a dose of 740 mg/m(2), one to three consecutive days depending on the chemotherapy regimen. Results. The hemoglobin, leukocyte, and platelet levels of the two groups were not statistically different. However, when comparing the Courses of the patients receiving the same medications at the same closes, in the group with amifostine, mean erythrocyte transfusion requirement was significantly reduced (P=0.025). In 31%, of the Courses with amifostine and 50% of the Courses Without amifostine, febrile neutropenia developed. Gastrointestinal system and hepatic toxicity Was Significantly reduced in the Courses with amifostine with respect to those without it (P=0.001). Vomiting, hypotension and nausea were the only side effects related to amifostine. Conclusion. Use of amifostine during the treatment of childhood cancers with intensive chemotherapy and/or radiotherapy significantly reduced the erythrocyte transfusion requirements of the patients as well as gastrointestinal and hepatic toxicity. Pediatr Blood Cancel 2009;52:829-833. (C) 2009 Wiley-Liss, Inc.Öğe Determination of School-Related Problems in Children Treated for Cancer(Sage Publications Inc, 2014) Yilmaz, Medine C.; Sari, Hatice Yildirim; Cetingul, Nazan; Kantar, Mehmet; Erermis, Serpil; Aksoylar, SerapThis descriptive and case-control study was carried out in a pediatric oncology outpatient clinic to determine the school-related physical, social, and psychological problems and problems experienced in academic achievement of children treated for cancer. The sample of the study consisted of 56 Turkish patients with cancer, aged 7-18 years, who were in remission and attending school as well as their parents, a control group of patients who did not have cancer, and their teachers. A Child Information Form, a Child Health Questionnaire Parent's Form of 50 questions, a Behavior Evaluation Scale for Children, and Young People and a Teacher's Report Form were used as data collection tools in the study. Of the children, 30.3% experienced various physical difficulties stemming from cancer therapy that affected their school life. The number of late enrollments, the number of children repeating a grade, and the rates of school absenteeism were also found to be higher in the survivors than in the controls.Öğe DIFFUSE PONTINE GLIOMAS OF THE CHILDHOOD: DOES TEMOZOLOMIDE IMPROVE SURVIVAL?(Wiley Periodicals, Inc, 2012) Anacak, Yavuz; Oniz, Haldun; Kantar, Mehmet; Kadioglu, Bengu; Kara, Gulsen; Kamer, Serra; Vergin, Canan; Cetingul, NazanÖğe Ege Üniversitesi Hastanesi çocukluk çağı tümörlerinde epidemiyoloji ve sağ kalım özellikleri(2019) Ataseven, Eda; Kantar, Mehmet; Anacak, Yavuz; Kamer, Serra; Ertan, Yeşim; Caner, Ayşe; Çetingül, NazanAmaç: Her yıl Dünyada 0-19 yaş arası yaklaşık 300.000 olgu kanser tanısı almaktadır. Gelişmiş ve gelişmekte olan ülkelerde çocukluk çağı kanserlerinin dağılımı ve sağ kalım hızlarında belirgin farklılık bildirilmektedir. Bu çalışmada amacımız merkezimizde kayıtlı olan çocukluk çağı kanser olgularının epidemiyolojik özelliklerini ve sağ kalım hızlarını değerlendirmektir. Gereç ve Yöntem: Merkezimizde 1992-2017 tarihleri arasında 0-19 yaş arasında kanser tanısı alan 4602 hastanın verileri Ege Üniversitesi Kanserle Savaş ve Araştırma Merkezi kayıtları kullanılarak geriye dönük olarak değerlendirildi. Yaşa, cinsiyete, yıllara göre tümör dağılımları ve genel sağ kalım hızları değerlendirildi. Bulgular: Olguların %55,3’ü erkek, %44,7’si kız ve erkek/kız oranı 1,23/1 idi. Olguların ortalama tanı yaşı 5,6 yıl idi. Merkezimizde en sık lösemi (%25,6), ikinci sıklıkta santral sinir sistemi tümörleri (%23,4), üçüncü sıklıkta ise lenfomalar (%14,2) görülmekteydi. Olguların ortalama izlem süresi 41,4 ay (0-316 ay) idi. Tüm olgular için beş yıllık genel sağ kalım hızı %74 saptandı. Sonuç: Merkezimizdeki kanser tiplerinin dağılımı ve genel sağ kalım hızları literatür ile benzerdir. Ülkemiz verileri ile karşılaştırıldığında genel sağ kalım hızlarımızın daha iyi olduğu görülmüştür. Bu sonuçlar sağ kalım hızlarının bölgeden bölgeye değiştiğini, bu değişimde hasta ve hasta yakınının farkındalık düzeyinin, gerekli tedaviye ulaşabilme imkanının ve multidisipliner merkezlerin varlığının önemini düşündürmektedir.Öğe Ehlers-Danlos sendromu ve kanama bulgularının sağıltımında desmopressin kullanımı(2001) Kavaklı, Kaan; Kantar, Mehmet; Özkınay, Ferda; Çoğulu, Özgür; Aydınok, Yeşim; Çetingül, Nazan; Kansoy, SavaşEhlers-Danlos sendromu (EDS), eklemlerde hiperekstansibilite, cutis laxa ile karakterize bir bağ doku hastalığıdır. Bu hastalıkta kolay morarma, epistaksis gibi kanama tabloları görülebilir. Kanamaların etiyolojisi kesin olarak bilinmemekle beraber sorunun kapiller yapının zayıflığından kaynaklandığı düşünülmektedir. EDS'lu hastalarda desmopressin (DDAVP) uygulaması özellikle IV, VI ve VIII.tiplerinde önerilmektedir. Biz de burada tip-II EDS düşünülen iki kardeşin hemostatik değerlendirmesini ve kız kardeşe uygulanan desmopressin sağıltımının sonuçlarını sunuyoruz.Öğe Enteral nutrition is feasible in pediatric stem cell transplantation patients(Wiley Periodicals, Inc, 2012) Bicakli, Derya Hopanci; Yilmaz, Medine C.; Aksoylar, Serap; Kantar, Mehmet; Cetingul, Nazan; Kansoy, SavasWe aimed to demonstrate whether enteral nutrition (EN) is feasible in daily practice of hematopoietic stem cell transplantation (HSCT).Nutritional records of 100 patients were evaluated. Patients with poor oral intake were fed by EN with tube. A total of 79 patients required nutritional support. Of them, 71 were fed by EN only. Five were fed by EN plus parenteral nutrition (PN),three were fed by PN only. Median duration of EN was 21 days. In the EN only group, 68% gained or maintained their weight. EN should be considered as a feasible option for nutrition support in children undergoing HSCT. Pediatr Blood Cancer 2012; 59: 13271329. (C) 2012 Wiley Periodicals, Inc.
- «
- 1 (current)
- 2
- 3
- »